New drug combo tested to control advanced lung cancer
NCT ID NCT02759614
Summary
This study tested whether adding the drug bevacizumab to standard treatment (erlotinib) works better for controlling advanced lung cancer in Chinese patients with specific genetic mutations. The trial involved 311 adults with advanced non-small cell lung cancer who had not received prior chemotherapy for their advanced disease. Researchers compared how long patients lived without their cancer getting worse when taking the two-drug combination versus the single drug alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences
Guangzhou, Guangdong, 510080, China
Conditions
Explore the condition pages connected to this study.